We are live on ! Find out more
LABU icon

Direxion Daily S&P Biotech Bull 3X ETF

37 hedge funds and large institutions have $51.9M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

17% more call options, than puts

Call options by funds: $87.4M | Put options by funds: $74.5M

0.99% more ownership

Funds ownership: 5.48%6.47% (+0.99%)

0% more capital invested

Capital invested by funds: $51.9M → $51.9M (+$16K)

14% less funds holding

Funds holding: 4337 (-6)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
37
Holders Change
-6
Holders Change %
-13.95%
% of All Funds
0.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
15
Reduced
6
Closed
15
Calls
$87.4M
Puts
$74.5M
Net Calls
+$12.9M
Net Calls Change
-$33.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$10.8M +$13.9M +117,965 +4,653%
Squarepoint
2
Squarepoint
New York
$8.67M +$10.9M +92,563 +2,462%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$5.48M +$6.66M +56,585 +1,324%
Goldman Sachs
4
Goldman Sachs
New York
$4.51M -$471 -4 -0%
VF
5
Virtu Financial
New York
$3.04M +$3.98M +33,807 New
QC
6
Quadrature Capital
United Kingdom
$2.94M -$4.64M -39,408 -55%
TRCT
7
Tower Research Capital (TRC)
New York
$2.43M +$2.04M +17,315 +178%
UBS Group
8
UBS Group
Switzerland
$2.2M +$2.88M +24,484 New
Wolverine Trading
9
Wolverine Trading
Illinois
$2.12M +$2.52M +21,401 +922%
GS
10
GTS Securities
New York
$2.04M -$2.9M -24,618 -52%
HF
11
HRT Financial
New York
$1.65M +$2.16M +18,321 New
Bank of America
12
Bank of America
North Carolina
$1.32M +$1.66M +14,098 +2,334%
Morgan Stanley
13
Morgan Stanley
New York
$918K +$126K +1,073 +12%
TCM
14
Traynor Capital Management
Pennsylvania
$773K -$256K -2,177 -20%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$477K +$6K +51 +1%
CIBC Private Wealth Group
16
CIBC Private Wealth Group
Georgia
$458K -$118K -1,000 -17%
MIG
17
McGuire Investment Group
Rhode Island
$406K -$14.1K -120 -3%
SBIA
18
Sheaff Brock Investment Advisors
Indiana
$360K
TSS
19
Two Sigma Securities
New York
$323K +$423K +3,593 New
SG Americas Securities
20
SG Americas Securities
New York
$305K +$22.7K +193 +6%
SS
21
SBI Securities
Japan
$244K +$319K +2,708 New
Citigroup
22
Citigroup
New York
$71.5K
PA
23
Parallel Advisors
California
$70.2K +$14.7K +125 +19%
SWM
24
Spire Wealth Management
Virginia
$67.7K +$88.5K +752 New
LC
25
Lindbrook Capital
California
$67K +$40K +340 +84%

LABU Hedge Fund Activity: Q4 2024 in Review

37 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q4 2024, worth a combined $51.9M — up 0.03% from $51.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of LABU and 9 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 15 added.

The largest buyer was Citadel Advisors, adding an estimated $13.9M. The largest seller was Tidal Investments, exiting entirely with an estimated $9.01M sold.

  • 37 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q4 2024, down from 43 in Q3 2024.
  • Funds reported $51.9M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q4 2024, up 0.03% quarter-over-quarter.
  • 9 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q4 2024 and 15 closed out, a net change of -6 holders.
  • The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q4 2024 was Citadel Advisors, an estimated $13.9M added.
  • The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q4 2024 was Tidal Investments, an estimated $9.01M sold.

Based on aggregated 13F filings for Q4 2024.